

Supplementary Table 5. Invasive disease-free survival according to adjuvant treatment stratified by tumor size

Treatment group	3-year	5-year	10-year	15-year	<i>p</i> value
Treatment (T1a)					0.40
No treatment	97.2%	82.2%	76.3%	38.2%	
Chemotherapy only	95.8%	95.8%	64.7%	43.1%	
Chemo + anti-HER2	100.0%	93.3%	93.3%	93.3%	
Chemotherapy (T1a)					0.43
No chemotherapy	97.2%	82.2%	76.3%	38.2%	
Chemotherapy	97.5%	94.9%	69.6%	52.2%	
Anti-HER2 therapy (T1a)					0.34
No anti-HER2	96.9%	88.9%	69.6%	38.6%	
Anti-HER2	100.0%	93.3%	93.3%	93.3%	
Treatment (T1b)					0.84
No treatment	100.0%	93.3%	83.0%	55.3%	
Chemotherapy only	93.1%	93.1%	93.1%	62.1%	
Chemo + anti-HER2	92.4%	92.4%	92.4%	NA	
Chemotherapy (T1b)					0.73
No chemotherapy	100.0%	93.3%	83.0%	55.3%	
Chemotherapy	93.2%	93.2%	93.2%	62.1%	
Anti-HER2 therapy (T1b)					0.73
No anti-HER2	95.6%	93.2%	87.4%	59.9%	
Anti-HER2	92.4%	92.4%	92.4%	NA	

HER2, human epidermal growth factor receptor 2; NA, not available.